Emil Kakkis

6.3k citations

73 papers · 5.0k · 2 hit papers · h-index 37

Impact in

Physiology top 0.5%
- Lysosomal Storage Disorders Research
Rheumatology top 0.5%
- Glycogen Storage Diseases and Myoclonus

Papers in

Physiology 46
- Lysosomal Storage Disorders Research 41
Epidemiology 24
- Trypanosoma species research and implications 15
- Inflammatory Myopathies and Dermatomyositis 6

Co-authors: Elizabeth F. Neufeld (5 shared papers)Michael Beck (4 shared papers)Joseph Muenzer (3 shared papers)Merry Passage (9 shared papers)Michael F. McEntee (6 shared papers)Gerald F. Cox (5 shared papers)Kenneth I. Berger (3 shared papers)J. E. Wraith (3 shared papers)
Journals: Molecular Genetics and Metabolism (20 papers)Proceedings of the National Academy of Sciences (4 papers)The Journal of Pediatrics (3 papers)Orphanet Journal of Rare Diseases (3 papers)Neuromuscular Disorders (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Emil Kakkis

73 papers receiving 4.8k citations

Emil Kakkis's Hit Papers

align trajectories log scale

Burosumab Therapy in Children with X-Linked Hypophosphatemia 2018 · 321 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2001 New England Journal of Medicine

Peers

Countries citing papers authored by Emil Kakkis

Since Specialization

Citations

This map shows the geographic impact of Emil Kakkis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil Kakkis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil Kakkis more than expected).

Fields of papers citing papers by Emil Kakkis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emil Kakkis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil Kakkis. The network helps show where Emil Kakkis may publish in the future.

Co-authors

The 25 scholars most cited alongside Emil Kakkis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emil Kakkis Line = papers co-authored together Emil Kakkis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 73 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Enzyme-Replacement Therapy in Mucopolysaccharidosis I New England Journal of Medicine ·Emil Kakkis, Joseph Muenzer, George E. Tiller, Lewis Waber, John W. Belmont, Merry Passage, Barbara Izykowski, J. Duncan Phillips, Robin Winkler Doroshow, Irv Walot, Richard H. Hoft, Kian Ti Yu, Susie Okazaki, D. C. Lewis, Ralph Lachman, Jerry N. Thompson, Elizabeth F. Neufeld Hit paper breakdown →	2001	525
2	Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase) The Journal of Pediatrics ·J. E. Wraith, L. Clarke, Michael Beck, Edwin H. Kolodny, Gregory M. Pastores, Joseph Muenzer, David M. Rapoport, Kenneth I. Berger, Stuart J. Swiedler, Emil Kakkis, Tanja Braakman, Elenie Chadbourne, Karen Walton–Bowen, Gerald F. Cox	2004	430
3	Burosumab Therapy in Children with X-Linked Hypophosphatemia New England Journal of Medicine ·Thomas O. Carpenter, Michael P. Whyte, Erik A. Imel, Annemieke M. Boot, Wolfgang Högler, Agnès Linglart, Raja Padidela, William van’t Hoff, Meng Mao, Chao-Yin Chen, Alison Skrinar, Emil Kakkis, Javier San Martín, Anthony A. Portale Hit paper breakdown →	2018	321
4	Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study The Journal of Pediatrics ·Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, Zi‐Fan Yu, Janet Wittes, Kenneth I. Berger, Mary S. Newman, Ann M. Lowe, Emil Kakkis, Stuart J. Swiedler	2006	285
5	Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I PEDIATRICS ·L. Clarke, J. E. Wraith, Michael Beck, Edwin H. Kolodny, Gregory M. Pastores, Joseph Muenzer, David M. Rapoport, Kenneth I. Berger, Marisa Sidman, Emil Kakkis, Gerald F. Cox	2008	261
6	Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α-l-Iduronidase (Laronidase) PEDIATRICS ·J. E. Wraith, Michael Beck, Roderick Lane, Ans van der Ploeg, Elsa Shapiro, Yong Xue, Emil Kakkis, Nathalie Guffon	2007	193
7	A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years Molecular Genetics and Metabolism ·Monica Sifuentes, Robin Winkler Doroshow, Richard H. Hoft, Greg Mason, Irwin Walot, Michael J. Diament, Susan Okazaki, Kenneth R. Huff, Gerald F. Cox, Stuart J. Swiedler, Emil Kakkis	2006	183
8	Efficacy of Sapropterin Dihydrochloride in Increasing Phenylalanine Tolerance in Children with Phenylketonuria: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study The Journal of Pediatrics ·Friedrich K. Trefz, Barbara K. Burton, Nicola Longo, Mercedes Martinez-Pardo Casanova, Daniel Gruskin, Alex Dorenbaum, Emil Kakkis, Eric Crombez, Dorothy K. Grange, Paul Harmatz, Mark Lipson, Andrzej Milanowski, Linda M. Randolph, Jerry Vockley, Chester B. Whitley, Jon A. Wolff, Judith D. Bebchuk, Heidi Christ‐Schmidt, Julia B. Hennermann	2009	156
9	Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I Biochemical and Molecular Medicine ·Emil Kakkis, Michael F. McEntee, Artur Schmidtchen, Elizabeth F. Neufeld, Daniel A. Ward, Rebecca E. Gompf, Stephen A. Kania, Cathy Bedolla, Shu-Lin Chien, Robert M. Shull	1996	150
10	Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII Proceedings of the National Academy of Sciences ·Carole Vogler, Beth Levy, Jeffrey H. Grubb, Nancy Galvin, Yun Tan, Emil Kakkis, Nadine Pavloff, William S. Sly	2005	144
11	Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid Molecular Genetics and Metabolism ·Patricia Dickson, Michael F. McEntee, Carole Vogler, Steven Q. Le, Beth Levy, Maryn Peinovich, Stephen R. Hanson, Merry Passage, Emil Kakkis	2007	140
12	Enzyme replacement in a canine model of Hurler syndrome. Proceedings of the National Academy of Sciences ·Robert M. Shull, Emil Kakkis, Michael F. McEntee, Stephen A. Kania, Adam J. Jonas, Elizabeth F. Neufeld	1994	139
13	Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I Molecular Genetics and Metabolism ·Emil Kakkis, Michael F. McEntee, Carole Vogler, Si-Hung Le, Beth Levy, Pavel V. Belichenko, William C. Mobley, Patricia Dickson, Stephen R. Hanson, Merry Passage	2004	133
14	A transcriptional repressor of c-myc Nature ·Emil Kakkis, Karen J. Riggs, William Gillespie, Kathryn Calame	1989	117
15	Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression American Journal of Medical Genetics Part A ·Maria-Veronica Muñoz-Rojas, Taiane Alves Vieira, Ronaldo Campelo da Costa, Simone Chaves Fagondes, Ângela Beatriz John, Laura Bannach Jardim, Leonardo Vedolin, Marcia Raymundo, Patricia Dickson, Emil Kakkis, Roberto Giugliani	2008	109
16	Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I Journal of Clinical Investigation ·Patricia Dickson, Maryn Peinovich, Michael F. McEntee, Thomas Lester, Steven Q. Le, Aimee Krieger, Hayden Manuel, Catherine Jabagat, Merry Passage, Emil Kakkis	2008	90
17	Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment—A retrospective chart review Molecular Genetics and Metabolism ·Jerry Vockley, Deborah Marsden, Elizabeth McCracken, Stephanie J. DeWard, Amanda Barone, Kristen Hsu, Emil Kakkis	2015	81
18	Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I The Lancet ·Revecca Kakavanos, Christopher T. Turner, John J. Hopwood, Emil Kakkis, Doug A. Brooks	2003	81
19	Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells Protein Expression and Purification ·Emil Kakkis, Anna Matynia, Adam J. Jonas, Elizabeth F. Neufeld	1994	80
20	Enzyme Replacement Therapy in Feline Mucopolysaccharidosis I Molecular Genetics and Metabolism ·Emil Kakkis, Edward H. Schuchman, Xingxuan He, Qi Wan, Stephen A. Kania, Staci Wiemelt, C Hasson, Thomas O’Malley, Margaret A. Weil, G.A. Aguirre, Diane E. Brown, Mark E. Haskins	2001	74

About Emil Kakkis

Emil Kakkis is a scholar working on Physiology, Epidemiology, Molecular Biology, Rheumatology and Organic Chemistry, having authored 73 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (41 papers), Glycogen Storage Diseases and Myoclonus (15 papers), Trypanosoma species research and implications (15 papers), Carbohydrate Chemistry and Synthesis (10 papers), Metabolism and Genetic Disorders (6 papers), Inflammatory Myopathies and Dermatomyositis (6 papers), Child Nutrition and Feeding Issues (4 papers) and Celiac Disease Research and Management (4 papers). The work is most often cited by research in Physiology (3.5k citations), Rheumatology (1.2k citations), Clinical Biochemistry (421 citations), Physiology (224 citations) and Epidemiology (1.7k citations). Emil Kakkis has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Elizabeth F. Neufeld, Michael Beck, Joseph Muenzer, Merry Passage, Michael F. McEntee, Gerald F. Cox, Kenneth I. Berger, J. E. Wraith, Stuart J. Swiedler and Kathryn Calame. Their work appears in journals such as Molecular Genetics and Metabolism, Proceedings of the National Academy of Sciences, The Journal of Pediatrics, Orphanet Journal of Rare Diseases and Neuromuscular Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Emil Kakkis

Impact in

Papers in i

In The Last Decade

Emil Kakkis

Emil Kakkis's Hit Papers

Peers

Countries citing papers authored by Emil Kakkis

Fields of papers citing papers by Emil Kakkis

All Works

About Emil Kakkis

Explore authors with similar magnitude of impact

Papers in